Themes US R&D Champions ETF(USRD.US)

Last Updated 19:00:00 ET
longbridge loading
Company Encyclopedia
View More
name
Themes US R&D Champions ETF
USRD.US
News
View More

Kimberly-Clark Files Registration Statement for Merger with Kenvue

Kimberly-Clark Corporation has announced a merger with Kenvue Inc., making Kenvue a wholly owned subsidiary. The merger will occur in two steps, with the SEC declaring the registration statement effective on December 16, 2025. A joint proxy statement/prospectus has been filed, but stockholders have initiated legal actions claiming insufficient disclosures regarding the deal.

Reuters·
US
KVUE
-0.35%
US
KMB
-1.09%
Reuters·
US
KVUE
-0.35%
US
KMB
-1.09%

ASML, Lam Research, Applied Materials surge. Why chip stocks are getting a boost.

Taiwan Semiconductor Manufacturing's heavy spending is great news for companies which sell machinery and other tools for chip manufacturing.

MSN·
US
LRCX
+2.52%
US
AMAT
+2.49%
US
TSM
+0.22%
MSN·
US
LRCX
+2.52%
US
AMAT
+2.49%
US
TSM
+0.22%

This Is What Whales Are Betting On Regeneron Pharmaceuticals

Investors are showing a bullish sentiment towards Regeneron Pharmaceuticals (NASDAQ:REGN), with significant options trades indicating potential price movements between $400 and $800. Recent data reveals a split sentiment among traders, with 36% bullish and 36% bearish. The stock is currently trading at $760.5, up 0.21%, with an anticipated earnings release in 16 days. Analysts have set target prices averaging $840, with one analyst raising their target to $860. Options trading presents higher risks but also greater profit potential for serious investors.

benzinga_article·
US
REGN
-1.20%
benzinga_article·
US
REGN
-1.20%

JPM26: Regeneron will not overpay in M&A deals amid lead asset patent expiries

Regeneron CEO Leonard Schleifer announced at the J.P. Morgan Healthcare conference that the company will prioritize in-house innovation over large M&A deals, especially as it faces patent expiries for its blockbuster drugs Eylea and Dupixent. Regeneron plans to invest $6 billion in R&D by 2026, focusing on developing next-generation assets and expanding drug indications. Despite industry trends favoring acquisitions, Schleifer warned that large M&A often leads to value destruction and overpayment. The company aims to transition patients to Eylea HD and is developing new treatments to offset future revenue losses from Dupixent's expected market exclusivity loss in 2031.

Pharmaceutical Technology·
US
REGN
-1.20%
Pharmaceutical Technology·
US
REGN
-1.20%

A Google-backed space stock is up 600% in a year. Here's why it could go even higher.

Planet Labs' stock has surged 588% over the past year, driven by optimism over its government contracts and new satellite technology. Wedbush analyst Dan Ives raised the price target to $28, citing strong demand for its services. The company recently secured a multiyear deal with Sweden's military worth over $500 million, adding to its existing contracts with the U.S. Planet Labs aims to launch advanced satellites capable of delivering AI-analyzed images within an hour. Google, a major investor, is collaborating on Project Suncatcher to develop solar-powered satellite constellations.

Dow Jones·
US
GOOG
-0.85%
US
GOOGL
-0.84%
US
PL
+1.77%
Dow Jones·
US
GOOG
-0.85%
US
GOOGL
-0.84%
US
PL
+1.77%
© 2026 Longbridge｜Disclaimer